Related Experiment Video
Updated: Aug 11, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Genomic features and its potential implication in bone oligometastatic NSCLC
Rongxin Liao1, Guangming Yi1, Lu Shen2
1Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
Objectives:
Emerging evidence have demonstrated that oligometastatic non-small cell lung cancer (NSCLC) can achieve clinical benefit from local consolidative therapy. Bone oligometastasis is common in advanced lung cancer, but little is known about its molecular features. The purpose of our study aimed to investigate the genomic landscape bone oligometastatic NSCLC.
Methods:
We collected paired blood and tissue samples from 31 bone oligometastatic NSCLC patients to make a comprehensive analysis of mutations by performing next-generation sequencing.
Results:
A total of 186 genomic mutations were detected from 105 distinct cancer-relevant genes, with a median number of 6 alterations per tumor. The most frequently mutated genes were EGFR (58%) and TP53 (55%), followed by KRAS (16%), CDKN2A (13%) and MET (13%). The signatures related to smoking, aging, homologous recombination deficiency and APOBEC were identified as the most important mutational processes in bone oligometastasis. The median tumor mutation burden was 4.4 mutations/Mb. Altogether, genetic alterations of bone oligometastasis are highly targetable that 74.19% of patients had at least one actionable alteration that was recommended for targeted therapy based on the OncoKB evidence. Of these patients, 16.13% had two actionable alterations that could potentially benefit from a different combination of targeted drugs to achieve better outcomes.
Conclusion:
Our research comprehensively elucidates the genomic features of bone oligometastatic NSCLC patients, which may optimize individualized cancer treatment in the era of precision medicine.
Insights
This study reveals that bone oligometastatic non-small cell lung cancer (NSCLC) has targetable genomic alterations. These findings support personalized treatment strategies for advanced NSCLC patients with bone metastases.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Oligometastatic non-small cell lung cancer (NSCLC) may benefit from local therapy.
- Bone oligometastasis is frequent in advanced lung cancer, but its molecular characteristics are poorly understood.
Purpose of the Study:
- To investigate the genomic landscape of bone oligometastatic NSCLC.
- To identify actionable targets for precision medicine in this patient population.
Main Methods:
- Comprehensive genomic analysis using next-generation sequencing.
- Analysis of paired blood and tissue samples from 31 bone oligometastatic NSCLC patients.
Main Results:
- Identified 186 mutations across 105 cancer-relevant genes, with EGFR and TP53 being the most frequent.
- Detected targetable alterations in 74.19% of patients, with 16.13% having multiple actionable mutations.
- Characterized mutational processes including smoking, aging, homologous recombination deficiency, and APOBEC signatures.
Conclusions:
- The study comprehensively elucidates the genomic features of bone oligometastatic NSCLC.
- Findings may optimize individualized cancer treatment strategies in the era of precision medicine.
More Related Videos
07:44Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
